Whilst hyperglycemia may lead to more severe COVID-19 disease, the risk of hypoglycemia has also been shown to be increased during the COVID-19 pandemic, especially for those patients on the hypoglycemic agents sulphonylureas and insulin (37) and, paradoxically, that may mean that those T2D patients with the tightest, most optimal control (but with greater risk of hypoglycaemia) may be at higher risk of infection. The gene discussed is INS; the disease is infection.